Trial Profile
A Phase II, Multicentre Study of Oral LBH589 in Patients With Chronic Phase Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two Fusion Gene of the BCR and ABL Genes (BCR-ABL) Tyrosine Kinase Inhibitors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis
- 03 Apr 2022 This trial has been completed in Netherland, according to European Clinical Trials Database record.
- 14 Jul 2021 Status changed from completed to discontinued.
- 22 Jun 2012 Planned number of patients changed from 120 to 130 and additional locations added as reported by European Clinical Trials Database record.